CN220812461U - Apparatus for preparing autologous thrombin - Google Patents

Abstract

The utility model discloses a preparation device of autologous thrombin, which belongs to the technical field of biomedical engineering, and comprises: the piston head of the piston of the activator cylinder is arranged in the inner container, the inner container is sleeved with the outer cylinder, and the piston seat of the piston can be fixedly connected with the outer cylinder. When the outer cylinder quantitatively moves upwards relative to the inner cylinder, the piston pushes the activator in the inner cylinder to be added into the test tube through the conducting tube, so that the activator is quantitatively added into the test tube, and the added activator is prevented from being polluted by the outside. The utility model has convenient operation and simple process, can effectively prevent external infection, and the prepared autologous thrombin has high activity and quick gel.

Description

Apparatus for preparing autologous thrombin

Technical Field

The utility model belongs to the technical field of biomedical engineering, and particularly relates to a preparation device of autologous thrombin.

Background

Thrombin acts as a coagulant and plays a very important role in the haemostasis process. If autologous blood is taken to prepare thrombin (ATS) for autologous therapy, not only rejection reactions but also viral infections and other side effects may be reduced.

When the sealed test tube is used for collecting autologous blood to prepare thrombin, the separation gel and the anticoagulant are added into the test tube in advance, and after the blood-collected test tube is put into a centrifugal machine for centrifugation, the blood in the test tube is centrifuged from top to bottom and layered into: plasma layer, leukocyte layer, erythrocyte layer. Firstly, extracting the upper layer of the plasma layer by using a syringe to prepare Platelet Poor Plasma (PPP), gently shaking the PRP tube to mix white blood cells into the residual plasma layer, extracting the plasma layer by using the syringe to prepare Platelet Rich Plasma (PRP), and respectively adding the extracted PPP and PRP into two test tubes; adding calcium salt into the test tube containing PPP to mix, then placing the test tube in a 37 ℃ incubator to incubate for 10min, and then allowing the gel to appear in the test tube, wherein platelets are activated to form Autologous Thrombin (ATS) in the gel, finally adding the gel into the test tube containing PRP, and further activating the PRP to release more growth factors and cytokines for autologous therapy.

The process for preparing the autologous thrombin is complex, inconvenient to operate, and easy to cause external infection and the like.

Disclosure of utility model

Aiming at the technical problems of complicated process, inconvenient operation, easy external infection and the like in the prior art for preparing thrombin, the utility model aims to provide a thrombin preparation device which has convenient operation, simple process, high activity and quick gel and can effectively prevent external infection.

In order to solve the technical problems, the technical scheme of the utility model is as follows:

An apparatus for producing autologous thrombin, comprising: an activator cylinder and a conduction tube;

The activator cylinder comprises an inner container, a piston and an outer cylinder, and a joint is arranged at the upper end of the inner container;

a first valve is arranged on the conduit and is connected with the joint;

The piston comprises a piston head and a piston connecting rod, the piston head is arranged in an inner container, one end of the piston connecting rod is connected with the piston head, the other end of the piston connecting rod is connected with the outer cylinder, the inner container is sleeved with the outer cylinder, and the outer cylinder moves relative to the inner container.

Preferably, a clamping hook is arranged on the outer periphery of the inner container, a clamping table is arranged on the outer periphery of the lower end of the inner container, and the outer cylinder can move between the clamping table and the clamping hook relative to the inner container.

Preferably, the outer cylinder comprises a sleeve, the sleeve is sleeved on the outer cylinder, and the outer cylinder is in threaded connection with the sleeve.

Preferably, the outer periphery of the outer cylinder is provided with scales along the axial direction, and the scale range is 0-10mm; the periphery of the sleeve is provided with fine scales along the circumferential direction, and the range of the fine scales is 0-10.

Preferably, a spring is sleeved on the piston connecting rod, one end of the spring is abutted against the lower end of the inner container, and the other end of the spring is connected with the outer cylinder.

Preferably, the first valve is a three-way valve, and the three-way valve is connected with the joint.

Preferably, a second valve is arranged on the conduit, and the second valve is a one-way valve.

Preferably, the second valve is used for connecting a test tube, a side connector is arranged on a tube body of the test tube, and the second valve is connected with the side connector.

Preferably, a control system is arranged on the outer cylinder and drives the outer cylinder to move up and down relative to the inner container.

Preferably, a control system and a motor are arranged on the outer cylinder, and the motor drives the outer cylinder to move up and down relative to the inner container.

Compared with the prior art, the utility model has the following advantages:

The utility model provides a thrombin preparation device and a thrombin preparation method which are convenient to operate, simple in working procedure, capable of effectively preventing external infection, high in thrombin activity and quick in gel, and short in time and large in gel volume for activating PRP to form gel by using the thrombin prepared by the thrombin preparation device.

Drawings

FIG. 1 is a schematic diagram of an apparatus for producing autologous thrombin;

FIG. 2 is a schematic view of an activator cartridge;

FIG. 3 is an exploded view of an activator cartridge;

FIG. 4 is a cross-sectional view of an activator cartridge;

FIG. 5 is an enlarged view of a three-way valve;

FIG. 6 is a schematic illustration of a one-way valve connecting a conduit with a test tube;

FIG. 7 is a flow chart of the preparation of autologous thrombin.

Detailed Description

The present utility model will be further described in detail with reference to specific examples, but embodiments of the present utility model are not limited thereto.

The apparatus for producing autologous thrombin of the present utility model is shown in FIGS. 1 to 6. The apparatus for producing autologous thrombin comprises: activator canister 1, conduction tube 2, valve 3 and test tube 4. The activator cylinder 1 is used for containing activator, the conduction pipe 2 is communicated with the activator cylinder 1 and the test tube 4, and a plurality of valves 3, such as a valve 31, a valve 32, a valve 33, a valve 34 and the like, which are arranged on the conduction pipe 2 can also be arranged on the conduction pipe 2 for controlling the on-off of the conduction pipe 2. When the activator cylinder 1 is communicated with the valve 31 and the test tube 4 is communicated with the valve 32, the valve 31 is opened, so that the activator in the activator cylinder 1 can flow into the conduit 2; the valve 32 is opened to allow the activator in the conduit 2 to flow further into the test tube 4.

The activator cartridge 1 is shown in particular in fig. 2-5. An activator cartridge 1 comprising: an inner container 12, a piston 13 and an outer cylinder 14. The inner container 12 is used for containing an activator, the piston head 131 of the piston 13 is arranged in the inner container 12, the inner container 12 is embedded into the outer cylinder 14, and the piston seat 133 of the piston 13 can be fixedly connected with the outer cylinder 14. When the outer cylinder 14 moves up and down along the inner cylinder 12, the piston 13 can be driven to move up and down, so that the piston head 131 moves up and down in the inner cylinder 12. Because the piston head 131 seals the inner container 12, the outer cylinder 14 further seals the inner container 12, thereby ensuring that the activator in the inner container 12 is not contaminated by the outside.

The inner container 12 is provided with the joint 123, the joint 123 is arranged at the top of the inner container 12, and the joint 123 can be directly connected with the conduit 2 or can be connected with the conduit 2 through the valve 3.

The periphery of the inner container 12 is provided with a clamping hook 121, the clamping hook protrudes downwards and forms a certain included angle with the periphery of the inner container 12, and two clamping hooks 121a and 121b can be symmetrically arranged. A clamping table 122 is arranged at the lower part of the clamping hook, and the clamping table 122 can be specifically arranged on the outer periphery of the lower end of the liner 12. When the outer cylinder 14 moves upwards relative to the inner container 12, the clamping hook can prop against the outer cylinder 14 so as to prevent the outer cylinder 14 from moving upwards further; when the outer tub 14 moves downward, the catch 122 catches the upper end opening of the outer tub 14 to prevent the outer tub 14 from continuing to move downward. In order to ensure the quantitative addition of the activator, the distance between the rising of the outer cylinder 14 from the catch 122 to the catch 121 is set to be the distance that the plunger 13 moves up and down relative to the inner container 12.

The piston 13 comprises a piston connecting rod, a piston head 131 and a piston seat 133, wherein the piston head 131 and the piston seat 133 are arranged at two ends of the piston connecting rod, the piston head 131 is arranged in the inner container 12, and the piston head 131 not only seals the lower end of the inner container 12, but also can push the activator in the inner container 12 into the conducting tube 2. The piston seat 133 is fixedly connected with the outer cylinder 14. The sealing ring 132 made of elastic material is arranged on the outer periphery of the piston head 131, and specifically, the sealing ring 132 can be embedded into a groove on the outer periphery of the piston head 131, so that the sealing effect between the piston head 131 and the inner container 12 is further improved when the piston head 131 moves up and down in the inner container 12. The piston connecting rod of the piston 13 is provided with a spring 16, and the spring 16 can be sleeved on the piston connecting rod of the piston 13, the upper end of the spring 16 abuts against the lower end of the inner container 12, and the lower end of the spring 16 is connected with the outer cylinder 14. The spring 16 is used for limiting the up-and-down movement range of the piston head 131, so that the piston head 131 can be prevented from being separated from the inner container 12 when moving downwards to the lower end of the inner container 12, and the piston head 131 can be prevented from being damaged when moving upwards to the top of the inner container 12.

The inner container 12 is embedded into the outer container 14, so that the inner container 12 is in sealing sleeve connection with the outer container 14, when the outer container 14 moves up and down relative to the inner container 12, the outer container 14 further drives the piston 13 to move up and down so as to drive the piston head 131 to move up and down in the inner container 12. When the outer cylinder 14 moves upwards relative to the inner cylinder 12, the piston 13 is driven to move upwards, and then the piston head 131 can push the activator in the inner cylinder 12 to enter the test tube 4 through the conduction pipe 2; when the activator in the inner container 12 runs out or the storage amount is insufficient, the outer cylinder 14 moves downwards relative to the inner container 12 to drive the piston 13 to move downwards, so that the activator can be added into the inner container 12 after the piston head 131 moves downwards to a limited position in the inner container 12. In order to ensure that a quantitative amount of activator is added to the test tube 4 each time, the outer cylinder 14 can be set to move quantitatively upwards relative to the inner cylinder 12 to drive the piston 13 to move quantitatively upwards, so that the activator in the inner cylinder 12 enters the test tube 4 through the guide tube 2 to be quantitative. In this way, not only is a quantitative activator added into the test tube 4 achieved, but also the added activator is protected from external contamination by the sealing of the activator flow path.

The outer cylinder 14 is provided with a control system connection, and the outer cylinder 14 can be connected with the control system. The control system comprises a control board and a power supply, and can also be provided with a motor, and the control system is connected with the outer cylinder 14 or directly connected with the bottom of the outer cylinder 14. The power supply can be a battery, an external power supply or a USB interface, etc., the power supply is started, the control system drives the outer cylinder 14 or the control system controls the motor to directly drive the outer cylinder 14 to automatically move up and down relative to the inner cylinder 12 and drive the piston 13 to move.

The device for preparing the autologous thrombin can be further provided with a mounting plate and a workbench, wherein the mounting plate is perpendicular to the workbench. An activator cylinder 1, a conducting tube 2 and a valve 3 are fixed on a mounting plate, a test tube loading frame is fixed on a workbench, and a test tube 4 can be inserted into the test tube loading frame. A power switch is arranged on the workbench and controls the power supply of the control system.

Due to the number of platelets in the blood that may occur from individual to individual or from individual to individual, there may be times and gel sizes at which the thrombin further forms a gel due to the presence of inactive platelets even if the activator is dosed. At this point, a small amount of activator is required to further activate the platelets to produce more thrombin. In order to control the amount of activator to be added so as to avoid waste, the outer tub 14 is provided with openings at the upper and lower ends, and a sleeve 15 may be provided on the outer tub 14. The sleeve 15 is sleeved on the outer cylinder 14, or an external thread 143 may be provided on the outer cylinder 14, an internal thread 153 may be provided on the sleeve 15, and the external thread 143 is connected with the internal thread 153, so that the sleeve 15 is in threaded connection with the outer cylinder 14. At this time, the piston seat 133 of the piston 13 may be fixed to the bottom of the sleeve 15, and the lower end of the spring 16 is connected to the sleeve 15. When thrombin gel in the test tube 4 is found to be long and the gel is dispersed, the sleeve 15 on the outer cylinder 14 can be further screwed up to drive the piston 13 to move upwards, so that the piston head 131 moves upwards slowly in the inner container 12, and a small amount of activator is added into the test tube 4.

In order to avoid wasting the activator, a scale 144 may be provided on the outer circumference of the outer cylinder 14 in the axial direction, in the range of 0-10mm, and the amount of activator added may be controlled by a change in scale of the upward movement of the sleeve 15 along the outer cylinder 14. Further, a fine scale 152 may be provided on the outer periphery of the sleeve 15 in the circumferential direction, and the range of the fine scale is 0 to 10. The 0mm position of the sleeve 15 on the outer tube 14 is set as the initial position, and when the sleeve 15 is screwed up clockwise on the outer tube 14, the addition amount of the activator is strictly controlled according to the change in the scale of the sleeve 15 moving up on the outer tube 14 and the change in the fine scale of the sleeve 15 on the outer tube 14.

The outer periphery of the outer cylinder 14 is provided with a boss 141, and two bosses 141a, 141b may be symmetrically provided on the upper part of the scale 144 of the outer cylinder 14 or at a position flush therewith. When the sleeve 15 moves upward in the outer barrel 14, the boss 141 can block the sleeve 15 from moving further upward, and can further control the dosing of a small amount of activator.

The first valve is valve 31, and the valve 31 is enlarged as shown in fig. 5. The valve 31 may be a three-way valve 31. The connecting portion 311 of the three-way valve 31 communicates with three valve ports a, b, c, and an included angle between every 2 adjacent valve ports is 120 °. The connecting part 311 is provided with a knob 312, and any two of the three valve ports a, b and c are communicated with each other when the knob 312 rotates 120 degrees, but the two valve ports are not communicated with the rest valve port. The joint 123 of the liner 12 is connected to the conduit 2 through the three-way valve 31, and the port a of the three-way valve 31 can be connected to the joint 123, the port b can be connected to the conduit 21, and the port c can be connected to the conduit 22.

If the dosage of the activator is not strictly controlled, the accelerator and the calcium salt as the components of the activator can be glass bead powder or Halloysite Nanotubes (HNTs) or other substances with negative electric properties, and the accelerator and the calcium salt are proportioned, and can be added into the test tube 4 by directly conducting through a conducting pipe 21 connected with a valve port b and a conducting pipe 22 connected with a valve port c.

If the amount of activator is to be strictly controlled, the activator is first prepared by mixing the accelerator with the calcium salt in a certain ratio, and a plurality of third valves may be provided on the conduit 2, the third valves including a two-way valve 33 and a two-way valve 34. The amounts of the accelerator and the calcium salt can be controlled by a two-way valve 33, and the addition amounts of the accelerator and the calcium salt can be further controlled by a two-way valve 34. The two-way valve 34 actually plays a role of switching, and when the two-way valve 34 is in an open state, the coagulant and the calcium salt can be added into the liner 12 through the conduit 21 connected with the valve port b and the joint 123 connected with the valve port a; when the two-way valve 34 is in the closed state, the addition of the activator to the liner 12 is stopped.

Rotating the knob 312 of the three-way valve 31 anticlockwise, when the valve port a and the valve port b of the three-way valve 31 are communicated, and when the piston 13 moves downwards, the coagulant and the activator configured by the calcium salt are added into the inner container 12 through the flow joint 123 of the conduction pipe 21 for storage and standby; further rotating knob 312 counterclockwise, at this time, port a is not in communication with port b, and port a is in communication with port c, and when outer cylinder 14 moves upward relative to inner container 12 to drive piston 13 to move upward, piston head 131 pushes up the activator in inner container 12, and the activator can flow through conduit 22 via connector 123 and be added into test tube 4.

The conduit 22 communicates the activator cartridge 1 with the test tube 4, and a second valve, which may be the valve 32, may be provided on the conduit 22. The valve 32 is a one-way valve, as shown in particular in fig. 6. The valve 32 comprises a valve port 321, a valve ball 322, a valve port 323 and a filter plug 324, the valve 32 controls the activator to circulate to the test tube 4 through the conduction tube 22, and the filter plug 324 of the valve 32 can allow a proper amount of air to enter and the activator to circulate smoothly without allowing the plasma in the test tube 4 to flow back into the conduction tube 22.

To avoid that the blood in the test tube 4 is subjected to air pollution or contact pollution, the test tube 4 may be a vacuum blood collection tube, a PRP tube or the like in which the tube body 43 is sealed with the tube cap 42. A side joint 432 may be provided on the side wall of the tube body 43 of the test tube 4, the side joint 432 is directly connected to the valve port 323 of the second valve, and the side joint 432 and the valve port 323 may also be connected by a replaceable disposable hose, so that the conductive tube 22 and the valve 32 are further prevented from being polluted by aerosol. For accurate blood collection, or for observing plasma, gel size, graduations may be provided on the tube body 43 of the test tube 4 and along the height direction of the tube body 43.

The method for producing autologous thrombin of the present utility model is shown in FIG. 7, using the apparatus for producing autologous thrombin described above. FIG. 7 is a flow chart of thrombin preparation using the autologous thrombin device described above, comprising the steps of:

Step a: test tube 4 is selected. The test tube 4 comprises a tube body 43 and a rubber plug 42, the test tube 4 is preset to be vacuum, and a vacuum blood collection tube, a PRP tube and the like can be selected.

The tube 43 may be a PRP tube, and the PRP tube may be added with a separation gel and an anticoagulant in advance.

Step b: whole blood was drawn. The amount of whole blood withdrawn using the PRP tube was (8-10) ml.

Step c: whole blood was centrifuged.

After the hand-held PRP tube is gently and repeatedly reversed, the blood is put into a centrifuge for centrifugal separation to prepare platelet-poor plasma (PLATELET RICH PLASMA, PPP) and platelet-rich plasma (Platelet poor plasma, PRP), and then the thrombin can be prepared by using PPP and PRP, or alternatively, thrombin can be prepared by using one of PPP and PRP. The method specifically comprises the following steps:

Step c1: c, centrifuging the whole blood prepared in the step c, wherein the components from bottom to top after the whole blood in the PRP tube is separated after centrifugation are as follows: erythrocytes, septums, buffy coat and plasma;

step c2: collecting the platelet poor plasma (PLATELET RICH PLASMA, PPP) from the upper plasma obtained in step c1, adding PPP to the first tube;

Step c3: after step c2 is completed, the PRP tube is inverted to suspend the buffy coat in the plasma to produce platelet rich plasma (Platelet poor plasma, PRP), the platelet rich plasma is collected and PRP is added to the second tube.

Step d: adding an activator.

Inserting a PRP tube into a test tube loading frame of a workbench, and starting a preparation device of the autologous thrombin by turning on a power supply; the three-way valve 31 and the valve 32 are opened, so that the valve port a and the valve port c of the three-way valve 31 are communicated, when the outer cylinder 14 moves upwards relative to the inner cylinder 12 to drive the piston 13 to move upwards, the piston head 131 pushes the activator in the inner cylinder 12 upwards, the activator can be added into the PRP tube through the connector 123 and the flow-through conduit 22, and then the activator is mixed with whole blood.

The activator can be mixed with the centrifuged blood plasma according to the volume ratio: 1: (3-7) mixing; optionally, the activator is mixed with the extracted PPP and PRP, and the activator occupies the total volume after mixing: 1/8-1/4 of the total weight of the composition.

The coagulant is glass bead powder or Halloysite Nanotubes (HNTs) or other substances with negative electrical properties. The calcium salt is added to the accelerator as a crystalline salt in solid form or as a salt solution in solution, and the activator may be pre-formulated for storage in the activator cartridge 1 or added directly to the test tube 4 as an additional solution at the time of use through the conduit 21 and conduit 22. The activator was formulated by mixing at room temperature in a proportion of 1ml of calcium salt solution containing (2-10) mg of the accelerator. Optionally adding 10% calcium chloride or 10% calcium gluconate to the coagulant to prepare activator, wherein the calcium salt is selected from calcium chloride, calcium carbonate, calcium sulfate, calcium gluconate and their mixture, and optionally preparing calcium salt from any one or more of them, such as 10% calcium chloride and 10% calcium gluconate.

Step e: and (5) standing. After standing for 30 minutes to allow sufficient contact, a gel forms in the PRP tube, a supernatant forms on the top, and the gel is squeezed to release thrombin from the supernatant.

Mixing may be accomplished by inversion, shaking, stirring, or vortexing, and mixing may be repeated once, multiple times, and periodically. After or during mixing, the whole blood, coagulant and calcium salt are in sufficient contact and form a gel after standing for a period of time. For example, the contact and standing time can be 10 minutes to 20 minutes, the contact and standing temperature can be 20 ℃ to 45 ℃, the contact and standing temperature can be room temperature or can be higher than the room temperature, and the gel formation can be accelerated when the contact and standing temperature is higher than the room temperature.

Step f: extracting thrombin solution. The supernatant was aspirated with a syringe to prepare an autologous thrombin solution.

To separate the gel to obtain a supernatant, the gel, clot and any other residual cellular components may be pelleted by centrifugation to the bottom of tube 4, which forms the supernatant. Squeezing the gel releases more thrombin and the thrombin-containing supernatant can be poured or extracted with a syringe. For example, the supernatant containing thrombin may be aspirated by centrifugation at 1500g for 5 minutes using a syringe or pipette. In order to maintain the activity of preparing thrombin, the thrombin solution may be stored at a low temperature, such as at a temperature of (2-8℃).

Because thrombin activates platelets, which release growth factors, cytokines, chemokines, and the like, thrombin converts fibrinogen in PRP to fibrin, further forming a more voluminous gel.

The gel of thrombin may be further prepared by step g: adding the extracted PRP into the thrombin solution prepared in the step f, so that the volume ratio of the thrombin solution to the PRP is as follows: (1-3): 10, and further forming a gel with a larger volume. The PRP may be collected by centrifugation of whole blood in the PRP tube, or may be collected by centrifugation of whole blood in the PRP tube.

Whole blood used in the present utility model is derived from the patient itself, and whole blood is drawn from the patient's body to prepare thrombin from the patient's body to prevent foreign viral infection or rejection. In order to improve the use effect, PPP and PRP can be extracted respectively after the whole blood is centrifugally separated, the activating agent is used for activating PPP to prepare thrombin, then the thrombin is mixed with the PRP, so that the thrombin further activates platelets in the PRP to release more growth factors, cytokines, chemokines and the like, and simultaneously, autologous thrombin can convert fibrinogen in the PRP into fibrin, thereby forming fibrin gel with larger volume. The prepared gel can be applied to a wound, can be used as a tissue sealant, and can promote the repair of the wound. Thrombin and PRP may be mixed prior to use or may be mixed at the wound site. The autologous thrombin product prepared by the method has no rejection problem of allogeneic thrombin and no possibility of being infected by virus.

The thrombin prepared by the method has high activity compared with thrombin prepared by using the coagulant and the calcium salt as the activators. In addition, the activation of PRP with thrombin according to the utility model to form a gel is bulky and has a short activation time under the same experimental conditions.

The foregoing is only a partial embodiment of the present utility model, and it should be noted that it will be apparent to those skilled in the art that modifications and adaptations can be made without departing from the principles of the present utility model, and such modifications and adaptations should and are intended to be comprehended within the scope of the present utility model.

Claims (10)

1. An apparatus for producing autologous thrombin, comprising: an activator cylinder and a conduction tube;

The activator cylinder comprises an inner container, a piston and an outer cylinder, and a joint is arranged at the upper end of the inner container;

a first valve is arranged on the conduit and is connected with the joint;

The method is characterized in that:

The piston comprises a piston head and a piston connecting rod, the piston head is arranged in an inner container, one end of the piston connecting rod is connected with the piston head, the other end of the piston connecting rod is connected with the outer cylinder, the inner container is sleeved with the outer cylinder, and the outer cylinder moves relative to the inner container.

2. The apparatus for producing autologous thrombin according to claim 1, wherein:

The outer periphery of the inner container is provided with a clamping hook, the outer periphery of the lower end of the inner container is provided with a clamping table, and the outer cylinder can move between the clamping table and the clamping hook relative to the inner container.

3. The apparatus for producing autologous thrombin according to claim 1, wherein:

The outer cylinder comprises a sleeve, the sleeve is sleeved on the outer cylinder, and the outer cylinder is in threaded connection with the sleeve.

4. The apparatus for producing autologous thrombin according to claim 3, wherein:

The outer periphery of the outer cylinder is provided with scales along the axial direction, and the scale range is 0-10mm; the periphery of the sleeve is provided with fine scales along the circumferential direction, and the range of the fine scales is 0-10.

5. The apparatus for producing autologous thrombin according to claim 1, wherein:

The piston connecting rod is sleeved with a spring, one end of the spring is abutted against the lower end of the inner container, and the other end of the spring is connected with the outer cylinder.

6. The apparatus for producing autologous thrombin according to claim 1, wherein:

The first valve is a three-way valve, and the three-way valve is connected with the joint.

7. The apparatus for producing autologous thrombin according to claim 1, wherein:

The guide pipe is provided with a second valve which is a one-way valve.

8. The apparatus for producing autologous thrombin according to claim 7, wherein:

The second valve is used for connecting the test tube, set up the side joint on the body of test tube, the second valve with the side joint is connected.

9. The apparatus for producing autologous thrombin according to claim 1, wherein:

the outer cylinder is provided with a control system, and the control system drives the outer cylinder to move up and down relative to the inner container.

10. The apparatus for producing autologous thrombin according to claim 1, wherein:

The outer cylinder is provided with a control system and a motor, and the motor drives the outer cylinder to move up and down relative to the inner container.